Hainan Poly Pharm Co Ltd
Hainan Poly Pharm. Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China and internationally. The company's dosage formulations comprise of tablets, capsules, granules, ointments, eye drops, pre-infusion, injection, lyophilization, and oral solutions. It also offers pharmaceutical preparations, active pharmaceutical ingredients, other raw materials, exc… Read more
Hainan Poly Pharm Co Ltd (300630) - Net Assets
Latest net assets as of September 2024: CN¥2.81 Billion CNY
Based on the latest financial reports, Hainan Poly Pharm Co Ltd (300630) has net assets worth CN¥2.81 Billion CNY as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.25 Billion) and total liabilities (CN¥3.45 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.81 Billion |
| % of Total Assets | 44.91% |
| Annual Growth Rate | 37.87% |
| 5-Year Change | 153.61% |
| 10-Year Change | N/A |
| Growth Volatility | 43.45 |
Hainan Poly Pharm Co Ltd - Net Assets Trend (2016–2023)
This chart illustrates how Hainan Poly Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hainan Poly Pharm Co Ltd (2016–2023)
The table below shows the annual net assets of Hainan Poly Pharm Co Ltd from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | CN¥2.91 Billion | +3.70% |
| 2022-12-31 | CN¥2.80 Billion | +10.26% |
| 2021-12-31 | CN¥2.54 Billion | +24.65% |
| 2020-12-31 | CN¥2.04 Billion | +77.95% |
| 2019-12-31 | CN¥1.15 Billion | +29.74% |
| 2018-12-31 | CN¥883.26 Million | +22.44% |
| 2017-12-31 | CN¥721.37 Million | +134.88% |
| 2016-12-31 | CN¥307.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hainan Poly Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1010.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.26 Billion | 43.35% |
| Other Components | CN¥1.65 Billion | 56.65% |
| Total Equity | CN¥2.91 Billion | 100.00% |
Hainan Poly Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Hainan Poly Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BranchOut Food Inc. Common Stock
NASDAQ:BOF
|
$36.69 Million |
|
Tailyn Technologies
TWO:5353
|
$36.71 Million |
|
Enterprise Group Inc
PINK:ETOLF
|
$36.72 Million |
|
PyroGenesis Canada Inc.
OTCQX:PYRGF
|
$36.73 Million |
|
Take Solutions Limited
NSE:TAKE
|
$36.69 Million |
|
PIE Industrial Bhd
KLSE:7095
|
$36.68 Million |
|
Grupa Azoty Zaklady Chemiczne Police SA
WAR:PCE
|
$36.67 Million |
|
Bai Sha Technology Co Ltd
TWO:8401
|
$36.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hainan Poly Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 2,802,510,631 to 2,906,225,473, a change of 103,714,842 (3.7%).
- Net income of 85,922,866 contributed positively to equity growth.
- Dividend payments of 94,920,748 reduced retained earnings.
- Other factors increased equity by 112,712,725.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥85.92 Million | +2.96% |
| Dividends Paid | CN¥94.92 Million | -3.27% |
| Other Changes | CN¥112.71 Million | +3.88% |
| Total Change | CN¥- | 3.70% |
Book Value vs Market Value Analysis
This analysis compares Hainan Poly Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.14x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.52x to 0.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.71 | CN¥0.89 | x |
| 2018-12-31 | CN¥2.10 | CN¥0.89 | x |
| 2019-12-31 | CN¥2.72 | CN¥0.89 | x |
| 2020-12-31 | CN¥4.67 | CN¥0.89 | x |
| 2021-12-31 | CN¥5.82 | CN¥0.89 | x |
| 2022-12-31 | CN¥6.42 | CN¥0.89 | x |
| 2023-12-31 | CN¥6.43 | CN¥0.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hainan Poly Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.59%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 2.16x
- Recent ROE (2.96%) is below the historical average (17.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 22.72% | 28.14% | 0.56x | 1.43x | CN¥39.07 Million |
| 2017 | 13.64% | 30.29% | 0.37x | 1.21x | CN¥26.27 Million |
| 2018 | 20.54% | 29.08% | 0.56x | 1.26x | CN¥93.10 Million |
| 2019 | 26.28% | 31.70% | 0.55x | 1.50x | CN¥186.55 Million |
| 2020 | 19.98% | 34.28% | 0.39x | 1.50x | CN¥203.54 Million |
| 2021 | 16.39% | 27.61% | 0.32x | 1.83x | CN¥162.43 Million |
| 2022 | 15.01% | 23.29% | 0.30x | 2.13x | CN¥140.36 Million |
| 2023 | 2.96% | 6.59% | 0.21x | 2.16x | CN¥-204.70 Million |
Industry Comparison
This section compares Hainan Poly Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hainan Poly Pharm Co Ltd (300630) | CN¥2.81 Billion | 22.72% | 1.23x | $36.69 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |